Biocardia Inc Net Assets
Biocardia Inc net assets. Based on the latest financial reports, Biocardia Inc (BCDA) has net assets worth $2.70 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($4.75 Million) and total liabilities ($2.06 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Biocardia Inc annual equity growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.70 Million |
| % of Total Assets | 56.78% |
| Annual Growth Rate | N/A |
| 5-Year Change | -91.37% |
| 10-Year Change | -95.65% |
| Growth Volatility | 3221.29 |
Net Assets of Biocardia Inc (1995–2025)
Net assets of Biocardia Inc from 1995 to 2025. This chart illustrates how Biocardia Inc's net assets have evolved over time, based on quarterly financial data. See BCDA net asset quality score to measure how much of total assets are equity-financed.
Annual Net Assets for Biocardia Inc (1995–2025)
The table below shows the annual net assets of Biocardia Inc from 1995 to 2025. For live market cap and overall valuation, see BCDA stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $895.00K | +6.93% |
| 2024-12-31 | $837.00K | +152.21% |
| 2023-12-31 | $-1.60 Million | -132.77% |
| 2022-12-31 | $4.89 Million | -52.85% |
| 2021-12-31 | $10.38 Million | -45.90% |
| 2020-12-31 | $19.18 Million | +709.11% |
| 2019-12-31 | $2.37 Million | -37.50% |
| 2018-12-31 | $3.79 Million | -65.91% |
| 2017-12-31 | $11.12 Million | -45.95% |
| 2016-12-31 | $20.58 Million | +48.44% |
| 2015-12-31 | $13.87 Million | +2.38% |
| 2014-12-31 | $13.54 Million | +1.76% |
| 2013-12-31 | $13.31 Million | +0.16% |
| 2012-12-31 | $13.29 Million | +2.40% |
| 2011-12-31 | $12.98 Million | +295.79% |
| 2010-12-31 | $3.28 Million | -77.75% |
| 2009-12-31 | $14.74 Million | +37.77% |
| 2008-12-31 | $10.70 Million | +17355.66% |
| 2007-12-31 | $61.28K | -56.71% |
| 2006-12-31 | $141.55K | -19.91% |
| 2005-12-31 | $176.73K | -81.66% |
| 2004-12-31 | $963.58K | -42.60% |
| 2003-12-31 | $1.68 Million | -19.79% |
| 2002-12-31 | $2.09 Million | -38.53% |
| 2001-12-31 | $3.40 Million | -45.67% |
| 2000-12-31 | $6.27 Million | +184.84% |
| 1999-12-31 | $2.20 Million | -35.29% |
| 1998-12-31 | $3.40 Million | -17.07% |
| 1997-12-31 | $4.10 Million | 0.00% |
| 1996-12-31 | $4.10 Million | +5814.60% |
| 1995-12-31 | $-71.75K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Biocardia Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 16824701000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Biocardia Inc Net Assets Breakdown (December 2025)
Biocardia Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $11.00K | 1.23% |
| Other Components | $169.23 Million | 18908.72% |
| Total Equity | $895.00K | 100.00% |
Biocardia Inc Competitors by Market Cap
The table below lists competitors of Biocardia Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nano Chem Tech Inc
KQ:091970
|
$13.96 Million |
|
Nuriplan Co. Ltd
KQ:069140
|
$13.96 Million |
|
Niocan Inc
V:NIO
|
$13.99 Million |
|
NexturnBioscience Co. Ltd
KQ:089140
|
$14.00 Million |
|
Inoviq Ltd
AU:IIQ
|
$13.95 Million |
|
Botanix Pharmaceuticals Ltd
AU:BOT
|
$13.94 Million |
|
Novatech Industries SA
PA:MLNOV
|
$13.94 Million |
|
Orbital Corporation Ltd
AU:OEC
|
$13.94 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biocardia Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 837,000 to 895,000, a change of 58,000 (6.9%).
- Net loss of 8,228,000 reduced equity.
- New share issuances of 8,690,000 increased equity.
- Other factors decreased equity by 404,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-8.23 Million | -919.33% |
| Share Issuances | $8.69 Million | +970.95% |
| Other Changes | $-404.00K | -45.14% |
| Total Change | $- | 6.93% |
Book Value vs Market Value Analysis
This analysis compares Biocardia Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.87x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1995-12-31 | $-11.64 | $0.92 | x |
| 1996-12-31 | $776.52 | $0.92 | x |
| 1997-12-31 | $776.52 | $0.92 | x |
| 1998-12-31 | $550.61 | $0.92 | x |
| 1999-12-31 | $346.29 | $0.92 | x |
| 2000-12-31 | $962.28 | $0.92 | x |
| 2001-12-31 | $429.99 | $0.92 | x |
| 2002-12-31 | $266.25 | $0.92 | x |
| 2003-12-31 | $214.60 | $0.92 | x |
| 2004-12-31 | $123.17 | $0.92 | x |
| 2005-12-31 | $21.41 | $0.92 | x |
| 2006-12-31 | $15.40 | $0.92 | x |
| 2007-12-31 | $6.67 | $0.92 | x |
| 2008-12-31 | $1369.13 | $0.92 | x |
| 2009-12-31 | $1534.46 | $0.92 | x |
| 2010-12-31 | $307.57 | $0.92 | x |
| 2011-12-31 | $1217.33 | $0.92 | x |
| 2012-12-31 | $1246.51 | $0.92 | x |
| 2013-12-31 | $1248.48 | $0.92 | x |
| 2014-12-31 | $1186.61 | $0.92 | x |
| 2015-12-31 | $1199.69 | $0.92 | x |
| 2016-12-31 | $332.04 | $0.92 | x |
| 2017-12-31 | $2.62 | $0.92 | x |
| 2018-12-31 | $13.34 | $0.92 | x |
| 2019-12-31 | $6.30 | $0.92 | x |
| 2020-12-31 | $28.43 | $0.92 | x |
| 2021-12-31 | $9.20 | $0.92 | x |
| 2022-12-31 | $4.14 | $0.92 | x |
| 2023-12-31 | $-1.14 | $0.92 | x |
| 2024-12-31 | $0.31 | $0.92 | x |
| 2025-12-31 | $0.13 | $0.92 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biocardia Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -919.33%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 3.81x
- Recent ROE (-919.33%) is below the historical average (-155.69%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1995 | 0.00% | 4.31% | 3.35x | 0.00x | $142.77K |
| 1996 | -14.63% | -17.65% | 0.72x | 1.15x | $-1.01 Million |
| 1997 | -14.63% | -17.65% | 0.72x | 1.15x | $-1.01 Million |
| 1998 | -17.65% | -15.79% | 0.93x | 1.21x | $-940.00K |
| 1999 | -59.09% | -30.95% | 1.31x | 1.45x | $-1.52 Million |
| 2000 | -24.64% | -38.72% | 0.54x | 1.19x | $-2.17 Million |
| 2001 | -64.00% | -56.36% | 0.92x | 1.23x | $-2.52 Million |
| 2002 | -58.62% | -31.01% | 1.34x | 1.41x | $-1.44 Million |
| 2003 | -28.59% | -11.77% | 1.54x | 1.57x | $-647.88K |
| 2004 | -75.03% | -19.23% | 2.20x | 1.77x | $-819.36K |
| 2005 | -459.65% | 0.00% | 0.00x | 5.08x | $-830.01K |
| 2006 | -65.56% | 0.00% | 0.00x | 1.24x | $-106.96K |
| 2007 | -123.11% | -11.73% | 7.38x | 1.42x | $-81.57K |
| 2008 | -54.22% | -457.41% | 0.11x | 1.07x | $-6.87 Million |
| 2009 | -34.46% | -271.70% | 0.12x | 1.06x | $-6.55 Million |
| 2010 | -350.99% | 0.00% | 0.00x | 1.66x | $-11.84 Million |
| 2011 | 74.45% | 80516.67% | 0.00x | 1.06x | $8.36 Million |
| 2012 | 2.30% | 491.94% | 0.00x | 1.00x | $-1.02 Million |
| 2013 | 0.14% | 7.09% | 0.02x | 1.00x | $-1.31 Million |
| 2014 | 1.73% | 54.80% | 0.03x | 1.00x | $-1.12 Million |
| 2015 | 2.32% | 62.28% | 0.04x | 1.00x | $-1.06 Million |
| 2016 | -50.09% | -1789.93% | 0.03x | 1.07x | $-12.37 Million |
| 2017 | -110.63% | -2569.52% | 0.04x | 1.22x | $-13.42 Million |
| 2018 | -368.86% | -2237.92% | 0.10x | 1.69x | $-14.37 Million |
| 2019 | -620.63% | -2071.69% | 0.09x | 3.24x | $-14.95 Million |
| 2020 | -78.24% | -10347.59% | 0.01x | 1.22x | $-16.92 Million |
| 2021 | -121.65% | -1243.45% | 0.06x | 1.51x | $-13.66 Million |
| 2022 | -243.52% | -881.14% | 0.14x | 2.00x | $-12.40 Million |
| 2023 | 0.00% | -2425.79% | 0.16x | 0.00x | $-11.41 Million |
| 2024 | -949.34% | -13700.00% | 0.02x | 4.45x | $-8.03 Million |
| 2025 | -919.33% | 0.00% | 0.00x | 3.81x | $-8.32 Million |
Industry Comparison
This section compares Biocardia Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Biocardia Inc (BCDA) | $2.70 Million | 0.00% | 0.76x | $13.95 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About Biocardia Inc
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina r… Read more